Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Roche and Vernalis identify lead candidate for treatment of obesity

June 6, 2001

Somatostatin receptor modulators in development at Takeda

June 5, 2001

PPAR agonists from Kyorin claimed for use in metabolic diseases

June 5, 2001

Agreement signed for U.S. promotion of AndroGel

June 5, 2001

SGLT2 inhibitors useful alone and in combination for Rx of diabetes and related disorders

June 1, 2001

Amylin submits MAA for Symlin in the E.U.

June 1, 2001

Novartis obtains license to Dr. Reddy's novel insulin sensitizer

June 1, 2001

Luveris reaches first market following late November approval by European Commission

June 1, 2001

Improvement in glucose tolerance and insulin secretion produced by Shionogi compounds

May 30, 2001

MCH antagonists and their utility described by Takeda

May 30, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...